- Ponatinib for CML
- Progress in the CML Landscape
- Treatment Options
- Sequencing Treatment
- Choosing the Appropriate TKI
- Monitoring Treatment Response
- Monitoring Adherence
- Switching Therapies
- Discontinuing Treatment
- Known Factors in TKI Resistance
- Managing Adverse Events
- Allogeneic Stem Cell Transplant
- CML: On the Horizon
- The Future of CML Treatment
Chronic Myeloid Leukemia News
More Chronic Myeloid Leukemia Information
Both the chemotherapy regimen selected and therapeutic dose intensity used in treatment factor into the calculation of neutropenia risk.
Traditional genetic testing historically included the sequential analysis of single and generally well-described genes involved in heritable cancers.
Some data suggest that psychotherapy may benefit patients with cancer, but higher-quality research is needed.
The effect of polypharmacy and noncancer mortality on patient survival and other outcomes in cancer varies by study.
Though it is clear that cancer is associated with an extreme financial burden, the extent of the burden varies widely.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|